Additive manufacturing (AM), which includes the 3-D printing process, may prove to be a game changer for biopharma as 3-D printing becomes widespread.

The AM process covers a range of categories defined by the American Society for Testing and Materials (ASTM) such as VAT photo-polymerization, binder jetting, material jetting, material extrusion, powder bed fusion, sheet lamination and directed energy deposition (1).